PepGen
Cambridge
MA
United States
40 articles about PepGen
-
PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference
5/4/2023
PepGen Inc. today announced that James McArthur, Ph.D., President and CEO of PepGen will present at the Bank of America Securities 2023 Healthcare Conference on Thursday, May 11th at 12:20pm EDT in Las Vegas, Nevada.
-
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting
4/17/2023
PepGen Inc. (Nasdaq: PEPG) today announced that it will present at the 2023 American Academy of Neurology (AAN) Annual Meeting, taking place on April 22-27, 2023 in Boston, Massachusetts.
-
PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference
4/13/2023
PepGen Inc. (Nasdaq: PEPG) today announced that James McArthur, Ph.D., President and CEO of PepGen will present at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20th at 8:00am EDT.
-
PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments
3/23/2023
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate developments.
-
PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference
3/22/2023
PepGen Inc. (Nasdaq: PEPG) will be presenting today nonclinical and clinical data of its Enhanced Oligonucleotide Delivery (EDO) platform at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas, Texas.
-
PepGen to Participate in the Stifel 2023 CNS Days Conference
3/21/2023
PepGen Inc. (Nasdaq: PEPG) today announced that James McArthur, Ph.D., President and CEO of PepGen will present at Stifel’s CNS Days Conference on Tuesday, March 28th at 1:30pm EST.
-
PepGen to Participate in the SVB Securities Global Biopharma Conference
2/9/2023
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, Ph.D., President and CEO of PepGen will present at SVB Securities’ Global Biopharma Virtual Conference on Thursday, February 16th 2023, at 10:40 A.M. EST.
-
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies
12/7/2022
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced new preclinical data supporting the progression of PGN-EDODM1, PepGen’s product candidate in development for the treatment of myotonic dystrophy type 1 (DM1), into clinical trials.
-
Many biopharma companies raised funds in 2022, but not enough to reach their next milestone. Investors have been constricting investments, so companies needing additional funding require a larger toolbox. -
According to a BIO report, less than a third of executive team members are women. BioSpace spoke with three influential women in biopharma to get their advice on breaking the executive barrier. -
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
11/14/2022
PepGen Inc. today announced NHP exon skipping data for PGN-EDO53, PepGen’s product candidate in development for the treatment of Duchenne muscular dystrophy (DMD) patients whose mutations are amenable to an exon 53 skipping approach.
-
PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
11/10/2022
PepGen Inc. reported financial results for the third quarter ended September 30, 2022 and highlighted recent corporate developments.
-
PepGen to Participate in the Stifel 2022 Healthcare Conference
11/8/2022
PepGen Inc. announced that James McArthur, Ph.D., President and CEO of PepGen will present at Stifel’s 2022 Annual Healthcare Conference in New York, New York on November 15th, 2022, at 9:45 A.M. ET.
-
PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress
10/13/2022
PepGen Inc. announced the presentation of data from its Duchenne muscular dystrophy program. The data are featured in a poster at the 27th International Hybrid Annual Congress of the World Muscle Society taking place in Halifax, Nova Scotia, Can.
-
New data from Axcella, PepGen, Dystrogen and Galecto are showing promise in challenging diseases, including NASH, Duchenne muscular dystrophy and myelofibrosis. -
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
9/28/2022
PepGen Inc. announced results from its completed Phase 1 healthy normal volunteer trial of PGN-EDO51, the company’s lead product candidate for the treatment of DMD patients whose mutations are amenable to an exon 51 skipping approach.
-
PepGen Appoints Habib Dable to Board of Directors
9/22/2022
PepGen Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced the appointment of Habib Joseph Dable to its Board of Directors.
-
Beyond the usual challenge of delivering high-quality data that answers meaningful questions, PepGen's Michelle Mellion is dedicated to “incorporating the patient’s voice into everything we do.” -
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
8/12/2022
PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2022.
-
PepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board
7/22/2022
PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Caroline Godfrey, Ph.D., one of PepGen’s scientific co-founders, to its Scientific Advisory Board.